Drug Profile
Research programme: epothilone therapeutics - Abraxis/Scripps Research Institute
Latest Information Update: 27 Oct 2010
Price :
$50
*
At a glance
- Originator The Scripps Research Institute
- Developer Abraxis BioScience
- Class Epothilones
- Mechanism of Action Tubulin modulators; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 31 Dec 2009 No development reported - Preclinical for Cancer in USA (unspecified route)
- 23 Aug 2007 Preclinical trials in Cancer in USA (unspecified route)